Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation

Transplantation

Volumn 87, Issue 4, 2009, Pages 606-614

  Yoshitomi, Mami ^a   Koshiba, Takaaki ^a   Haga, Hironori ^b   Li, Ying ^a   Zhao, Xiangdong ^a   Cheng, Donghua ^a   Miyagawa, Aya ^b   Sakashita, Hiromi ^b   Tsuruyama, Tatsuaki ^a   Ohe, Hidenori ^a   Ueda, Mikiko ^a   Okamoto, Shinya ^a   Egawa, Hiroto ^a   Wood, Kathryn ^c   Sakaguchi, Shimon ^d   Manabe, Toshiaki ^b   Tanaka, Koichi ^e   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KYOTO UNIVERSITY   (Japan)

^e FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Liver transplantation; Protocol biopsy; Tolerance

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; AGE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; ADOLESCENT; ADULT; BIOPSY; DONOR; GRAFT SURVIVAL; IMMUNOLOGY; INFANT; LIVER; LIVER CIRRHOSIS; METHODOLOGY; PATHOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STATISTICS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; BIOPSY; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; FEMALE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 65649106140     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318195a7cb     Document Type: Article

References (37)

1. Ueda M, Oike F, Ogura Y, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl 2006; 12: 1326.
2. Jonas S, Neuhaus R, Junge G, et al. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int Immunopharmacol 2005; 5: 125.
3. Matthews JB, Ramos E, Bluestone JA. Clinical trials of transplant tolerance: Slow but steady progress. Am J Transplant 2003; 3: 794.
4. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: Emerging developments. Transpl Immunol 2007; 17: 108.
5. Auchincloss H Jr. In search of the elusive Holy Grail: The mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001; 1: 6.
6. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72: 449.
7. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunol 2007; 17: 94.
8. Cortesini R. Tolerance in clinical liver transplantation introductory remarks. Transplant Immunol 2007; 17: 81.
9. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997; 25: 658.
10. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
11. Tachibana T, Onodera H, Tsuruyama T, et al. Increased intratumor Valpha24-positive natural killerTcells: Aprognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005; 11: 7322.
12. Mazariegos GV, Reyes J,Marino IR, et al. Weaningof immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243.
13. Ramos HC, ReyesJ,Abu-ElmagdK,et al. Weaningof immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59: 212.
14. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
15. Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005; 37: 1708.
16. Eason JD, Cohen AJ, Nair S,et al. Tolerance: Is it worth the risk? Transplantation 2005; 79: 1157.
17. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702.
18. Tullius SG, Tilney NL. Both alloantigen-dependent and-independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
19. Cuturi MC, Josien R, Douillard P, et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the alpha 1 helix of the first domain of HLA-B7 01. Transplantation 1995; 59: 661.
20. Knechtle SJ. Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 2000; 12: 552.
21. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
22. Remuzzi G, Rossini M, Imberti O, et al. Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet 1991; 337: 750.
23. Sablinski T, Hancock WW, Tilney NL, et al. CD4 monoclonal antibodies in organ transplantation - A review of progress. Transplantation 1991; 52: 579.
24. Subbotin V, Sun H, Aitouche A, et al. Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation 1997; 64: 690.
25. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985; 55: 369.
26. Bergese SD, Klenotic SM, Wakely ME, et al. Apoptosis in murine cardiac grafts. Transplantation 1997; 63: 320.
27. Goss JA, Nakafusa Y, Finke EH, et al. Induction of tolerance to islet xenografts in a concordant rat-to-mouse model. Diabetes 1994; 43: 16.
28. Sprent J, Hurd M, Schaefer M, et al. Split tolerance in spleen chimeras. J Immunol 1995; 154: 1198.
29. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057.
30. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
31. Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
32. Yoshizawa A, Ito A, Li Y, et al. The roles of CD25 + CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 2005; 37: 37.
33. McLean AJ, Cogger VC, Chong GC, et al. Age-related pseudocapillarization of the human liver. J Pathol 2003; 200: 112.
34. Haagsma EB, van den Berg AP, Porte RJ, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008; 14: 547.
35. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811.
36. Ibarra H, Riedemann S, Reinhardt G, et al. Anti-HEV in dialysis and renal transplant patients in an endemic region in Chile. Clin Nephrol 1998; 50: 267.
37. Buffet C, Laurent-Puig P, Chandot S, et al. A high hepatitis E virus seroprevalence among renal transplantation and haemophilia patient populations. J Hepatol 1996; 24: 122.